QUICKLINKS AND VIEW OPITONS
Acomplia (rimonabant) : 3% of patients dropped out of studies due to depression
Friday, November 16, 2007 10:21 am Email this article
Three percent of patients given Acomplia (rimonabant) dropped out of studies due to depression compared to 1.4 percent given a placebo according to an analysis by Arnie Astrup and others from the University of Copenhagen in Frederiksberg, Denmark. This means that dropouts due to depression are 2.5 times as likely with Acomplia (rimonabant) than with placebo.
This is despite the fact that "[all of] the included trials excluded patients with existing depression, or those with a history [of depression]," Astrup noted. REFERENCE
Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A. Efficacy and safety of the weight-loss drug rimonabant: A meta-analysis of randomised trials. Lancet. 2007 Nov 17, 370(9600):1671-72.
AUTHOR’S CONTACT INFORMATION
Prof Arne Astrup
The Department of Human
Nutrition, Faculty of Life Sciences
University of Copenhagen
Articles on the same subject can be found here:
Please feel free to share your comments about this article.
© Copyright 2003-2017 - Larry Hobbs - All Rights Reserved.